Teladoc Health Announces Board and Executive Changes

Ticker: TDOC · Form: 8-K · Filed: 2024-07-05T00:00:00.000Z

Sentiment: neutral

Topics: management-change, executive-compensation, board-of-directors

Related Tickers: TDOC

TL;DR

Teladoc shake-up: board members out, new exec comp plans in.

AI Summary

Teladoc Health, Inc. announced on June 28, 2024, changes in its board of directors and executive compensation. The filing details the departure of certain officers and the election of new directors, alongside updates to compensatory arrangements for key executives.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy, governance, and future performance.

Risk Assessment

Risk Level: medium — Changes in leadership and compensation can indicate internal restructuring or strategic shifts that may impact future performance.

Key Players & Entities

FAQ

What specific roles have been affected by the departure of certain officers?

The filing indicates the departure of certain officers but does not specify the exact roles in this summary.

Who are the newly elected directors?

The filing mentions the election of directors but does not list their names in this summary.

What are the key details of the updated compensatory arrangements?

The filing notes updates to compensatory arrangements for certain officers but does not provide specific details in this summary.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on June 28, 2024.

What is the principal executive office address for Teladoc Health, Inc.?

The principal executive office is located at 2 Manhattanville Road Suite 203 Purchase, NY 10577.

From the Filing

0001477449-24-000168.txt : 20240705 0001477449-24-000168.hdr.sgml : 20240705 20240705160509 ACCESSION NUMBER: 0001477449-24-000168 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240628 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240705 DATE AS OF CHANGE: 20240705 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Teladoc Health, Inc. CENTRAL INDEX KEY: 0001477449 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 043705970 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37477 FILM NUMBER: 241102651 BUSINESS ADDRESS: STREET 1: 2 MANHATTANVILLE ROAD STREET 2: SUITE 203 CITY: PURCHASE STATE: NY ZIP: 10577 BUSINESS PHONE: 2036352002 MAIL ADDRESS: STREET 1: 2 MANHATTANVILLE ROAD STREET 2: SUITE 203 CITY: PURCHASE STATE: NY ZIP: 10577 FORMER COMPANY: FORMER CONFORMED NAME: Teladoc, Inc. DATE OF NAME CHANGE: 20091123 8-K 1 tdoc-20240628.htm 8-K tdoc-20240628 FALSE 0001477449 0001477449 2024-06-28 2024-06-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 8-K ___________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 28, 2024 ___________________________________ Teladoc Health, Inc. (Exact name of registrant as specified in its charter) ___________________________________ Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) 04-3705970 (I.R.S. Employer Identification No.) 2 Manhattanville Road Suite 203 Purchase , NY 10577 (Address of principal executive offices and zip code) ( 203 ) 635-2002 (Registrant's telephone number, including area code) ___________________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common stock, par value $0.001 per share TDOC The New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company     ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.02     Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 28, 2024, Teladoc Health, Inc. (the “Company”) terminated without cause the employment of Laizer Kornwasser, President, Enterprise Growth and Global Markets, in connection with a change in the Company's executive reporting structure, effective July 1, 2024. Mr. Kornwasser will remain employed with the Company as Advisor to the Chief Executive Officer until Augus

View on Read The Filing